人血清白蛋白(human serum albumin,HSA)融合技术是蛋白质药物长效化改造的一种通用技术,也是目前国内外生物制药研究的热点。在HSA融合技术的研究中,不同融合方式的融合蛋白活性的差异,提高HSA融合蛋白的表达产量以及HSA融合蛋白在表达过程中所出现的降解问题成为制约该技术发展的关键。现就人血清白蛋白融合技术在药物长效化改造应用中所涉及的融合方式以及融合蛋白的高效表达和降解问题进行了综述,希望为HSA融合技术的广泛应用提供一定的技术参考。 Human serum albumin (HSA) fusion technology is a universal technology for the long-term modification of protein drugs, and is also a hot spot in biopharmaceutical research at home and abroad. In the study of HSA fusion technology, the differences in the activity of fusion proteins between different fusion methods, the increase of the expression yield of HSA fusion protein and the degradation of HSA fusion protein during the expression process are the key factors that restrict the development of this technology. The integration of human serum albumin fusion technology in drug long-term transformation applications and the high expression and degradation of fusion proteins are reviewed. It is hoped to provide some technical references for the wide application of HSA fusion technology.